Current Oncology Reports

, Volume 14, Issue 6, pp 539–543

Surgery for Relapsed Ovarian Cancer: When Should it Be Offered?

Gynecologic Cancers (NS Reed, Section Editor)


Whilst cytoreductive surgery is the mainstay treatment for primary ovarian cancer, its role in relapse is still unclear. Surgery in platinum-sensitive recurrent ovarian cancer might be beneficial if it results in complete resection of the disease. Clinical scores could help to identify suitable patients. Level I evidence is still missing; however, two randomized trials (DESKTOP III and GOG 213) are ongoing.


Ovarian cancer Surgery Recurrent ovarian cancer Secondary cytoreductive surgery AGO score 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295–303.PubMedCrossRefGoogle Scholar
  2. 2.
    Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, Kommoss S, Heitz F, Traut A, du Bois A. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol. 2011;121:615–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.PubMedCrossRefGoogle Scholar
  4. 4.
    du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234–44.PubMedCrossRefGoogle Scholar
  5. 5.
    •• Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21(4):771–5. Report of the 4th Ovarian Cancer Consenus Conference. PubMedCrossRefGoogle Scholar
  6. 6.
    Harter P, Hilpert F, Mahner S, et al. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Rev Anticancer Ther. 2010;10(1):81–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Sehouli J, Meier W, Wimberger P, et al. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A randomized phase-III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR). J Clin Oncol 2012; 30 (suppl; abstr 5031)Google Scholar
  8. 8.
    Aghajanian C, Blank SV, Goff BA, et al. OCEANS:ARandomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2012 Apr 2.Google Scholar
  9. 9.
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92(9):699–708.PubMedCrossRefGoogle Scholar
  11. 11.
    Sehouli J, Stengel D, Harter P, et al. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2011;29(2):242–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Baumann K, Pfisterer J, Wimberger P, et al. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group. Gynecol Oncol. 2011;123:27–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Harter P, Hilpert F, Mahner S, et al. Role of cytoreductive surgery in recurrent ovarian cancer. Expert Rev Anticancer Ther. 2009;9(7):917–22.PubMedCrossRefGoogle Scholar
  14. 14.
    Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.PubMedCrossRefGoogle Scholar
  15. 15.
    Morris M, Gershenson DM, Wharton JT. Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy. Gynecol Oncol. 1989;33:1–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Meier W, Römisch M, Hepp H. The value of reoperation in the treatment of ovarian cancer. Geburtshilfe Frauenheilkd. 1993;53(1):30–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Segna RA, Dottino PR, Mandeli JP, Konsker K, Cohen CJ. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol. 1993;11(3):434–9.PubMedGoogle Scholar
  18. 18.
    Harter P, du Bois A. 17. The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Curr Opin Oncol. 2005;17(5):505–14.PubMedCrossRefGoogle Scholar
  19. 19.
    Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88(1):144–53.PubMedCrossRefGoogle Scholar
  20. 20.
    Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2001;83(3):504–12.PubMedCrossRefGoogle Scholar
  21. 21.
    Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer. 2004;100(6):1152–61.PubMedCrossRefGoogle Scholar
  22. 22.
    • Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702–10. First multicenter study defining the surgical endpoint of complete resection in surgery for recurrent ovarian cancer. PubMedCrossRefGoogle Scholar
  23. 23.
    Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106(9):1933–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Oksefjell H, Sandstad B, Tropé C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol. 2009;20(2):286–93.PubMedCrossRefGoogle Scholar
  25. 25.
    Tian WJ, Jiang R, Cheng X, et al. Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction. J Surg Oncol. 2010;101(3):244–50.PubMedGoogle Scholar
  26. 26.
    Sehouli J, Richter R, Braicu E, et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol. 2010;102(6):656–62.PubMedCrossRefGoogle Scholar
  27. 27.
    • Zang RY, Harter P, Chi DS, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011;105(7):890–6. Large review including data of more than 1000 patients with surgery for relapse. PubMedCrossRefGoogle Scholar
  28. 28.
    Harter P, Hilpert F, Mahner S, Kommoss S, Heitz F, Pfisterer J, du Bois A. Prognostic factors for complete debulking in first and second line ovarian cancer. Int J Gynecol Cancer. 2009;19:S14–7.PubMedCrossRefGoogle Scholar
  29. 29.
    •• Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21(2):289–95. First prospective study with successfull validation of a score predicting surgical outcome. PubMedCrossRefGoogle Scholar
  30. 30.
    Tian WJ, Chi DS, Sehouli J, et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012;19(2):597–604.PubMedCrossRefGoogle Scholar
  31. 31.
    Kommoss S, Rochon J, Harter P, et al. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann Surg Oncol. 2010;17(1):279–86.PubMedCrossRefGoogle Scholar
  32. 32.
    Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107(1):77–85.PubMedCrossRefGoogle Scholar
  33. 33.
    Sehouli J, Savvatis K, Braicu EI, et al. Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis. Int J Gynecol Cancer. 2010;20(8):1331–40.PubMedGoogle Scholar
  34. 34.
    Galaal K, Naik R, Bristow RE, et al. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2010;6:CD007822.PubMedGoogle Scholar
  35. 35.
    Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21(4):750–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Philipp Harter
    • 1
  • Florian Heitz
    • 1
  • Andreas du Bois
    • 1
  1. 1.Department of Gynecology and Gynecologic OncologyKliniken Essen-MitteEssenGermany

Personalised recommendations